A Monte Carlo Simulation for Modelling Outcomes of AIDS Treatment Regimens

被引:0
作者
Anke Richter
Brett Hauber
Kit Simpson
Josephine A. Mauskopf
Dongping Yin
机构
[1] RTI Health Solutions,
[2] RTI Health Solutions,undefined
[3] University of South Carolina,undefined
[4] Merck & Co.,undefined
来源
PharmacoEconomics | 2002年 / 20卷
关键词
Viral Load; Viral Suppression; Medical Care Cost; Viral Load Test; Viral Load Level;
D O I
暂无
中图分类号
学科分类号
摘要
Healthcare providers are often faced with the need to make treatment decisions about antiretroviral therapy regimens for patients with HIV infection without definitive information as to the optimal sequencing of drug regimens. In this paper we describe our model developed to simulate the impact of differing drug sequencing strategies used in the treatment of patients with HIV/AIDS. In addition, we present the methods used to estimate the efficacy and duration of antiretroviral therapies to populate the model at baseline. We conducted a hypothetical application of the model using three alternative series of therapies: a series containing no drug therapy, a series starting with a protease inhibitor-containing regimen, and a series starting with a non-nucleoside reverse transcriptase inhibitor-containing regimen.
引用
收藏
页码:215 / 224
页数:9
相关论文
共 56 条
  • [1] Carpenter C.C.J.(2000)Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel JAMA 283 381-90
  • [2] Cooper D.A.(2001)The cost-effectiveness of combination antiretroviral therapy in HIV disease N Engl J Med 344 824-31
  • [3] Fischl M.A.(1998)A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection Med Decis Making 18 S93-S105
  • [4] Freedberg K.A.(1999)Current issues in Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV: using simulation modelling to inform clinical guidelines [abstract] Med Decis Mak 194 523-12
  • [5] Losina E.(1999)Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens AIDS 13 1207-80
  • [6] Weinstein M.C.(2001)Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia N Engl J Med 344 472-8
  • [7] Paltiel A.D.(2000)Immune restoration with antiretroviral therapies: implications for clinical management JAMA 284 223-600
  • [8] Sharfstein J.A.(2000)Treatmentwith indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus and prior antiretroviral therapy Acomparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individual with HIV infection: selection of thymidine analog regimen therapy (START I) AIDS 14 1591-9
  • [9] Seage G.R.(1997)Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up N Engl J Med 337 734-41
  • [10] Goldie S.J.(1999)A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy JAMA 280 35-93